| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Nanofin targets nicotinic acetylcholine receptors (nAChRs) as a ganglion blocker. It acts as a nicotinic acetylcholine receptor antagonist, blocking transmission at autonomic ganglia. This mechanism results in antihypertensive effects by reducing sympathetic outflow. The compound is a neuropathic blocker used for mild to moderate hypertension. Its piperidine structure enables its activity as a receptor antagonist. Nanofin also serves as an intermediate for pharmaceutical synthesis.
|
|---|---|
| ln Vitro |
In vitro, Nanofin demonstrates nicotinic acetylcholine receptor antagonist activity. As a ganglion blocker, it inhibits neurotransmission at autonomic ganglia. The compound's antihypertensive effects are mediated through this mechanism. Nanofin is used as an intermediate for pharmaceuticals and as a catalyst for polymerizations. Its receptor binding and functional antagonism have been characterized in various in vitro assays. The compound's piperidine structure is important for its biological activity.
|
| ln Vivo |
In vivo, Nanofin is a neuropathic blocker with antihypertensive effect used for mild to moderate hypertension. It acts as a ganglion blocker alkaloid with nicotinic acetylcholine receptor antagonist action. The compound has been used in the study of hypertension. Nanofin is also known as 2,6-dimethylpiperidine and is used as an intermediate for pharmaceuticals. Further in vivo studies have evaluated its antihypertensive efficacy and safety.
|
| Enzyme Assay |
Nanofin receptor binding assays involve measuring affinity for nicotinic acetylcholine receptors. Radioligand binding displacement studies are performed using membranes from cells expressing nAChRs. Functional antagonism is assessed by measuring inhibition of nicotinic receptor-mediated signaling such as calcium mobilization or electrophysiological responses. Antihypertensive activity is assessed in relevant animal models. Assays are performed in appropriate buffer systems with positive controls such as known nAChR antagonists. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Nanofin cell-based assays are conducted in cells expressing nicotinic acetylcholine receptors. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with Nanofin at varying concentrations. Receptor activation is assessed by measuring calcium mobilization or electrophysiological responses. Antagonist activity is confirmed by measuring inhibition of agonist-induced responses. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive (e.g., known nAChR antagonists) and negative (vehicle) controls.
|
| Animal Protocol |
Nanofin in vivo studies are conducted in animal models of hypertension. Animals are treated with Nanofin via oral administration or injection. Blood pressure is monitored using appropriate techniques. Antihypertensive efficacy is assessed by measuring reduction in blood pressure. For toxicological studies, animals are exposed to Nanofin at varying doses and monitored for adverse effects. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Nanofin (MW 113.20 g/mol, C7H15N) is a small piperidine derivative. It is miscible with water. The compound is stable under recommended storage conditions. Nanofin is also known as 2,6-dimethylpiperidine, 2,6-lupetidine, Lupetidine, and Naniopinum. It is used as an intermediate for pharmaceuticals and as a catalyst for polymerizations. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Nanofin is generally well-tolerated at therapeutic doses used for hypertension research. The compound is a ganglion blocker alkaloid with established safety profiles. Its antihypertensive effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
Nanofin (2,6-dimethylpiperidine, 2,6-lupetidine) is a neuropathic blocker with antihypertensive effect used for mild to moderate hypertension. It is a ganglion blocker alkaloid with nicotinic acetylcholine receptor antagonist action. The compound is a piperidine derivative used as an intermediate for pharmaceuticals and as a catalyst for polymerizations. Nanofin is also known as Naniopinum and Lupetidine. All applications are limited to non-human research use.
|
| Molecular Formula |
C7H15N
|
|---|---|
| Molecular Weight |
113.2007
|
| Exact Mass |
113.12
|
| CAS # |
504-03-0
|
| Related CAS # |
5072-45-7 (hydrochloride)
|
| PubChem CID |
68843
|
| Appearance |
Colorless to light yellow liquid（Density：0.84 g/cm3）
|
| Density |
0.8±0.1 g/cm3
|
| Boiling Point |
127.1±0.0 °C at 760 mmHg
|
| Melting Point |
<-20ºC
|
| Flash Point |
11.7±0.0 °C
|
| Vapour Pressure |
11.3±0.2 mmHg at 25°C
|
| Index of Refraction |
1.417
|
| LogP |
1.92
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
62.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1CCCC(C)N1
|
| InChi Key |
SDGKUVSVPIIUCF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H15N/c1-6-4-3-5-7(2)8-6/h6-8H,3-5H2,1-2H3
|
| Chemical Name |
2,6-dimethylpiperidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~883.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (22.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (22.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (22.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.8339 mL | 44.1696 mL | 88.3392 mL | |
| 5 mM | 1.7668 mL | 8.8339 mL | 17.6678 mL | |
| 10 mM | 0.8834 mL | 4.4170 mL | 8.8339 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
